JOURNAVX
GrowthNDAORALTABLETPriority Review
Approved
Jan 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
8
Data completeness
5/8 — Partial
Priority Review
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JOURNAVX (suzetrigine) is an oral small-molecule sodium channel antagonist approved by the FDA on January 30, 2025, for the treatment of pain conditions. It works by blocking sodium channels to reduce neuronal excitability and pain signal transmission. The drug represents Vertex Pharmaceuticals' entry into the pain management market with a novel mechanism.
Growth14.1 years to LOE
Early-stage growth trajectory with no direct competitors currently present, positioning the brand team to establish market share and build institutional infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (8)
Suzetrigine (Journavx) as Multimodal Therapy for Pain Management in Adults Undergoing Surgery for Hip Fracture
Started Jan 2027
79 enrolled
Hip Fractures (ICD-10 72.01-72.2)Post Operative Analgesia
Suzetrigine Added to Multimodal Analgesia for Women Undergoing Minimally Invasive Hysterectomy
Started Nov 2026
123 enrolled
Postoperative Pain
Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery
Started Oct 2026
100 enrolled
Opioid Consumption, PostoperativeMultimodal AnalgesiaUreteroscopy+2 more
Suzetrigine for Postoperative Pain After Total Ankle Replacement
Started Oct 2026
28 enrolled
Ankle OsteoarthritisPostoperative PainAcute Pain
Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty
Started Jul 2026
75 enrolled
Knee ArthritisKnee Osteoarthritis
Worked on JOURNAVX at Vertex Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.